-

05:57:03 PM

HZNP Stock News

HZNP - Horizon Therapeutics Plc

03/16/23 11:55 AM

Nasdaq : HZNP

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

DEALING DISCLOSURE UNDER RULE 8.1 (c) AND OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022. BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS. If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1 (c), copy table 2...

RHEA-AI

negative

03/14/23 11:15 AM

Nasdaq : HZNP

New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical optic nerve lesions in people with NMOSD. These findings are being presented during the 49 th annual meeting of the North American Neuro-Ophthalmology Society March 11-16, 2023, in Orlando,...

RHEA-AI

neutral

03/12/23 12:00 PM

Nasdaq : HZNP

Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)

Horizon Therapeutics plc today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease patients with DON, the majority of whom had not previously responded to other treatments. DON is a complication of TED characterized by thyroid-related impairment of visual function and can lead to permanent sight loss related to...

RHEA-AI

neutral

03/01/23 4:05 PM

Nasdaq : HZNP

Horizon Therapeutics plc - Rule 2.12 Announcement

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, Horizon confirms that, as of the close of business on February 23, 2023, Horizon’ s issued ordinary share capital is comprised of 228,832,390 ordinary shares, nominal value $0.0001 per share and 40,000 deferred ordinary shares of €1.00 each. The Company confirms that as of...

RHEA-AI

neutral

03/01/23 7:02 AM

Nasdaq : HZNP

earnings

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Horizon Therapeutics plc today announced fourth-quarter and record full-year 2022 financial results. “2022 marked another impressive year for Horizon, with double-digit net sales growth across our commercial portfolio and significant progress executing on our strategy to maximize the value of our growth medicines, expand our global presence and...

RHEA-AI

positive

02/28/23 8:00 AM

Nasdaq : HZNP

Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program

Horizon Therapeutics plc today announced that applications for its 2023# RAREis Global Advocate Grant are open through March 31, 2023. To increase impact and support advocates who are catalysts for rare disease community needs,# RAREis will grant 50 groups with a one-time $5,000 grant. “Addressing problems in rare disease can mean the difference in saving a...

RHEA-AI

very positive

02/24/23 4:05 PM

Nasdaq : HZNP

Horizon Therapeutics plc Announces Voting Results from Special Shareholder Meetings

Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc.. Horizon Therapeutics plc, a public limited company incorporated in Ireland announces today that, in relation to the offer for the Company by Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc., a Delaware corporation, pursuant to which...

RHEA-AI

neutral

02/23/23 8:00 AM

Nasdaq : HZNP

covid-19

New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines

Horizon Therapeutics plc today announced new data from two post-hoc analyses of the N-MOmentum clinical trial of UPLIZNA for the treatment of neuromyelitis optica spectrum disorder will be presented at the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum, February 23-25, 2023, in San Diego. UPLIZNA is the first and...

RHEA-AI

negative

01/30/23 8:00 AM

Nasdaq : HZNP

earnings

Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023

Horizon Therapeutics plc announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets. Investor Relations: Tina Ventura Senior Vice President, Chief Investor Relations Officer Investor-relations@horizontherapeutics.com. U.S. Media: Geoff Curtis...

RHEA-AI

neutral

01/27/23 4:05 PM

Nasdaq : HZNP

Rule 15 (c) Announcement – Horizon Therapeutics plc

On December 12, 2022, the board of directors of Horizon Therapeutics plc, a public limited company incorporated in Ireland and the board of directors of Amgen Inc., a Delaware corporation, announced that they had reached agreement on the terms of a cash offer for the Company by Pillartree Limited, a newly formed private limited company wholly owned by Amgen,...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next